Urologic Oncology: Seminars and Original Investigations
Volume 29, Issue 6 , Pages 756-763 , November 2011

Predictors of response to sequential sunitinib and the impact of prior VEGF-targeted drug washout in patients with metastatic clear-cell renal cell carcinoma

  • Aymen A. Elfiky, M.D., M.A., M.P.H.

      Affiliations

    • Dana-Farber/Harvard Cancer Center, Harvard Medical School, Boston, MA 02115, USA
    • ,
  • Daniel C. Cho, M.D., M.S.

      Affiliations

    • Dana-Farber/Harvard Cancer Center, Harvard Medical School, Boston, MA 02115, USA
    • ,
  • David F. McDermott, M.D.

      Affiliations

    • Dana-Farber/Harvard Cancer Center, Harvard Medical School, Boston, MA 02115, USA
    • ,
  • Jonathan E. Rosenberg, M.D.

      Affiliations

    • Dana-Farber/Harvard Cancer Center, Harvard Medical School, Boston, MA 02115, USA
    • ,
  • Barry Fortner, Ph.D.

      Affiliations

    • P4 Healthcare, Lakeland, TN 38002, USA
    • ,
  • Lucia Antràs, Ph.D.

      Affiliations

    • Analysis Group, Inc., Boston, MA 02115, USA
    • ,
  • Kristina Chen, Ph.D.

      Affiliations

    • Analysis Group, Inc., Boston, MA 02115, USA
    • ,
  • Mei Sheng Duh, Ph.D.

      Affiliations

    • Analysis Group, Inc., Boston, MA 02115, USA
    • ,
  • Sujata S. Jayawant, Ph.D.

      Affiliations

    • Analysis Group, Inc., Boston, MA 02115, USA
    • ,
  • William K. Oh, M.D.

      Affiliations

    • Dana-Farber/Harvard Cancer Center, Harvard Medical School, Boston, MA 02115, USA
    • ,
  • Michael B. Atkins, M.D.

      Affiliations

    • Dana-Farber/Harvard Cancer Center, Harvard Medical School, Boston, MA 02115, USA
    • ,
  • Toni K. Choueiri, M.D.

      Affiliations

    • Dana-Farber/Harvard Cancer Center, Harvard Medical School, Boston, MA 02115, USA
    • Corresponding Author InformationCorresponding author. Tel.: +1-617-632-5456; fax: +1-617-632-2165

Received 18 December 2009 ,Revised 26 January 2010 ,Accepted 26 January 2010.

References 

  1. Dvorak HF. Vascular permeability factor/vascular endothelial growth factor: A critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy. J Clin Oncol. 2002;20:4368–4380
  2. Rini BI, Small EJ. Biology and clinical development of vascular endothelial growth factor-targeted therapy in renal cell carcinoma. J Clin Oncol. 2005;23:1028–1043
  3. Motzer RJ, Rini BI, Bukowski RM, et al. Sunitinib in patients with metastatic renal cell carcinoma. JAMA. 2006;295:2516–2524
  4. Motzer RJ, Michaelson MD, Redman BG, et al. Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J Clin Oncol. 2006;24:16–24
  5. Motzer RJ, Hutson TE, Tomczak P, et al. Sunitinib vs. interferon alfa in metastatic renal-cell carcinoma. N Engl J Med. 2007;356:115–124
  6. Escudier B, Eisen T, Stadler WM, et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med. 2007;356:125–134
  7. Escudier B, Pluzanska A, Koralewski P, et al. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: A randomized, double-blind phase III trial. Lancet. 2007;370:2103–2111
  8. Sablin MP, Negrier S, Ravaud A, et al. Sequential sorafenib and sunitinib for renal cell carcinoma. J Urol. 2009;182:29–34
  9. Tamaskar I, Garcia JA, Elson P, et al. Antitumor effects of sunitinib or sorafenib in patients with metastatic renal cell carcinoma who received prior anti-angiogenic therapy. J Urol. 2008;179:81–86
  10. Dudek AZ, Zolnierek J, Dham A, et al. Sequential therapy with sorafenib and sunitinib in renal cell carcinoma. Cancer. 2009;115:61–67
  11. Wilhelm SM, Carter C, Tang L, et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res. 2004;64:7099–7109
  12. Escudier B, Choueiri TK, Oudard S, et al. Prognostic factors of metastatic renal cell carcinoma after failure of immunotherapy: New paradigm from a large phase III trial with shark cartilage extract AE 941. J Urol. 2007;178:1901–1905
  13. Choueiri TK, Rini B, Garcia JA, et al. Prognostic factors associated with long-term survival in previously untreated metastatic renal cell carcinoma. Ann Oncol. 2007;18:249–255
  14. Choueiri TK, Garcia JA, Elson P, et al. Clinical factors associated with outcome in patients with metastatic clear-cell renal cell carcinoma treated with vascular endothelial growth factor-targeted therapy. Cancer. 2007;110:543–550
  15. Feldman DR, Baum MS, Ginsberg MS, et al. Phase I trial of bevacizumab plus escalated doses of sunitinib in patients with metastatic renal cell carcinoma. J Clin Oncol. 2009;27:1432–1439
  16. Zimmermann K, Schmittel A, Steiner U, et al. Sunitinib treatment for patients with advanced clear-cell renal-cell carcinoma after progression on sorafenib. Oncology. 2009;76:350–354
  17. Eichelberg C, Heuer R, Chun FK, et al. Sequential use of the tyrosine kinase inhibitors sorafenib and sunitinib in metastatic renal cell carcinoma: A retrospective outcome analysis. Eur Urol. 2008;54:1373–1378
  18. Rini BI, Michaelson MD, Rosenberg JE, et al. Antitumor activity and biomarker analysis of sunitinib in patients with bevacizumab-refractory metastatic renal cell carcinoma. J Clin Oncol. 2008;26:3743–3748

☆ This research was supported in part by the DF/HCC Kidney Cancer SPORE.

PII: S1078-1439(10)00036-0

doi: 10.1016/j.urolonc.2010.01.008

Urologic Oncology: Seminars and Original Investigations
Volume 29, Issue 6 , Pages 756-763 , November 2011

Article Tools

* Image Usage & Resolution